Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 16.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,554,475 shares of the company’s stock after buying an additional 360,201 shares during the period. Impax Asset Management Group plc’s holdings in Health Catalyst were worth $20,793,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. First Light Asset Management LLC increased its stake in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after acquiring an additional 3,221,408 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after purchasing an additional 1,184,131 shares during the period. Primecap Management Co. CA increased its position in Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock worth $15,205,000 after purchasing an additional 305,079 shares in the last quarter. Daventry Group LP increased its position in Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares in the last quarter. Finally, Nepsis Inc. raised its holdings in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Trading Down 0.3 %

NASDAQ HCAT opened at $7.68 on Tuesday. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The company’s fifty day moving average price is $7.96 and its two-hundred day moving average price is $7.08.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) EPS. Analysts predict that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Analyst Ratings Changes

HCAT has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI raised their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Piper Sandler reduced their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Stephens reduced their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.90.

Insider Buying and Selling

In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at approximately $1,036,024.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,187 shares of company stock worth $226,171. Insiders own 2.50% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.